1. Introduction {#sec1}
===============

Cystic fibrosis (CF), a chronic and progressive suppurative lung disease, affects more than 30,000 people in the Unites States ([@bib18]; [@bib27]). A hallmark of CF disease is declining lung function over time, which has been attributed to recurrent lung infection and lung inflammation ([@bib34]; [@bib35]). Bronchiectasis, airway inflammation, and decreased lung function is evident even in infants and young children with CF ([@bib38], [@bib39]; [@bib41]).While *Staphylococcus aureus* and *Pseudomonas aeruginosa* are important drivers of airway inflammation in older children and adults, infants and young children may have negative culture results for these bacterial species ([@bib7]; [@bib33]; [@bib43]). Recent studies to better understand the role of bacteria in CF disease in infants and young children have used culture-independent next generation sequencing (NGS).

Studies of bronchoalveolar lavage (BAL) fluid from infants and young children with CF show a diverse community of aerobes and anaerobes that normally comprise the flora of the upper airway ([@bib15]; [@bib22]). Colonization or infection with a recognized CF pathogen is associated with a decrease in bacterial diversity ([@bib7]; [@bib22]). Reduced bacterial diversity in the lower airway is also associated with the use of prophylactic antibiotics ([@bib24]).

Comparisons between BAL fluid obtained from infants and young children with CF and non-CF controls have consistently shown that children with CF have decreased microbial diversity in the lower airways ([@bib8]; [@bib29]; [@bib44]). Differences in microbial community composition appear to be driven by both the prevalence of certain bacteria and their relative abundance ([@bib8]; [@bib29]; [@bib44]). Differences in community composition are also more extreme when CF children are experiencing a pulmonary exacerbation ([@bib8]). Studies of the upper airway microbiome in infants and young children with CF and healthy controls using nasopharyngeal swabs have also found differences in community composition, driven in part by antibiotic administration ([@bib21]; [@bib26]).

While the above studies primarily explored differences in the upper airways from nasopharyngeal samples or the lower airways from samples obtained by bronchoscopy, national guidelines in the United States recommend quarterly oropharyngeal (OP) swabs as a surrogate of lower airway microbiota ([@bib3]; [@bib16]). The primary objective of this study is to identify differences in the oropharyngeal microbiome of infants and young children with CF and healthy controls. The secondary objective is to examine longitudinal changes in the oropharyngeal microbiome of infants and young children with CF, and the potential impact of CF transmembrane conductance regulator (CFTR) modulators on microbial diversity.

2. Materials & methods {#sec2}
======================

2.1. Study design and participants {#sec2.1}
----------------------------------

### 2.1.1. Children with cystic fibrosis {#sec2.1.1}

The creation of a bio- and data repository was approved 08 Dec 2015 by the Institutional Review Board (Pro6781) at Children\'s National Hospital (CNH). Parental permission (written consent) for study participation was obtained prior to respiratory sample collection and extraction of data from electronic medical records.

#### 2.1.1.1. Inclusion criteria {#sec2.1.1.1}

All children and adults with CF, diagnosed by sweat chloride or genetic testing, who receive care at CNH are eligible to participate in the biorepository. Participants are recruited during routinely scheduled clinical encounters in the CNH CF Center. For this study, children had to be between 0-6 years of age with at least four consecutive respiratory samples available in the biorepository.

#### 2.1.1.2. Subject encounters, data collection, and respiratory sample collection {#sec2.1.1.2}

Demographic information for each study participant was collected after study enrollment, including age, gender, race/ethnicity, and CFTR genotype. After each regularly scheduled clinic visit or hospital admission, the participant\'s medical record is accessed to record visit specific information, including antibiotics received and clinical culture results. Each encounter was noted to be either a well visit or a sick visit, based on documentation of at least 4 of 12 characteristics consistent with Fuchs criteria for pulmonary exacerbation ([@bib9]). Respiratory samples (Copan Eswabs in 1 mL liquid Amies transport media collected from the oropharynx) were collected from the microbiology laboratory at CNH after they were no longer needed for clinical purposes and were then processed and stored in the biorepository. The clinical microbiology laboratory uses MicroScan (BeckmanCoulter) for identification and antibiotic susceptibility testing (via broth dilution) of CF respiratory samples. The respiratory samples used in this study were obtained from the biorepository.

### 2.1.2. Children who served as healthy controls {#sec2.1.2}

The recruitment of healthy controls was approved 24 Aug 2016 by the CNH Institutional Review Board (Pro7992). Parental permission (written consent) was obtained for all subjects.

#### 2.1.2.1. Inclusion and exclusion criteria {#sec2.1.2.1}

Children between 0-6 years of age, with no history of chronic upper airway or lung medical conditions, who have not been on antibiotics for the prior 30 days, and who match the age and gender of the comparison subjects with cystic fibrosis were recruited for the study.

#### 2.1.2.2. Potential subject identification {#sec2.1.2.2}

Patients coming to be seen at the Goldberg Center for Community Pediatric Health at CNH for well child checks were identified as potential candidates for study inclusion. Their medical charts were reviewed to determine if 1) they had any chronic medical conditions and 2) they met the demographic profile to match with a CF participant.

#### 2.1.2.3. Subject encounters and respiratory sample collection {#sec2.1.2.3}

The potential subjects were approached by the principal investigator (PI) or other study staff to discuss participation. Screening questions were asked to determine if any exclusion criteria were met, including verification of any chronic upper airway or lung medical conditions and recent use of antibiotics. If they still met enrollment criteria, the study was explained in detail to the family. The PI or study staff completed the informed consent process. The family was asked to complete a study questionnaire and study staff obtained a single oropharyngeal (OP) swab. The electronic medical record was then accessed and the parental responses to the questionnaire were verified against previously documented information, including past medical history and medications.

2.2. Experimental procedures {#sec2.2}
----------------------------

### 2.2.1. Data management {#sec2.2.1}

All study data were maintained and managed in a unified REDCap database ([@bib12]).

### 2.2.2. Respiratory sample processing {#sec2.2.2}

Copan eSwabs with 1 mL liquid Amies media were used for respiratory sample collection. After collection, the OP swab samples were stored in a 4 °C refrigerator prior to processing. The swab was removed and the Amies media transferred to a sterile 1.5 mL microcentrifuge tube. The media was then pelleted through centrifugation (12,000 *g* × 10 min). Supernatants were removed and bacterial pellets were frozen at -80 °C until they underwent DNA extraction.

### 2.2.3. Bacterial DNA extraction {#sec2.2.3}

Pelleted bacterial cells were rapidly thawed and mixed with 1 mL of sterile phosphate buffered saline (PBS). Bacterial DNA was extracted using a QIAamp DNA Microbiome kit (Qiagen, Valencia CA), following the protocol as outlined by the company.

### 2.2.4. Next generation sequencing and bioinformatics {#sec2.2.4}

Sequencing was performed by the University of Michigan Host Microbiome Initiative (Ann Arbor MI) ([@bib14]; [@bib37]). Briefly, extracted DNA was amplified for the V4 region of the 16S rRNA marker-gene using PCR primers (forward primer GTGCCAGCMGCCGCGGTAA; reverse primer TAATCTWTGGGVHCATCAGG) ([@bib14]). The PCR cycle for the amplification of the V4 region was as follows: 95 °C × 2 min (1x); 95 °C × 20 s, 55 °C 15 s, 72 °C 5 min (30x); 72 °C 10 min (1X); 4 °C (until sequencing). Libraries were normalized using SequalPrep Normalization Plate Kit (Life Technologies, Carlsbad CA), and DNA concentration measured using Kapa Biosystems Library Quantification Kit (Kapa Biosystems, Wilmington MA). A MiSeq Reagent Kit V2 (500 cycle) was used to perform the dual-index sequencing. Specifically, 2 × 250 base pair (bp) paired-end reads were produced, allowing for full overlap of the forward and reverse reads of the V4 region ([@bib14]). ZymoBIOMICS Microbial Community Standards (Zymo Research, Irvine CA), were included as positive sequencing controls and PCR-free water were included as negative sequencing controls in each MiSeq run.

Raw FASTQ files were processed in mothur v.1.39.5 (<https://www.mothur.org/wiki/MiSeq_SOP>, accessed 7 Jun and 25 Sept 2018) ([@bib14]; [@bib36]). As per the standard operating procedure, we first combined paired reads. We next looked across the alignment to see if there were any base pairs that were mismatched, to correct any low quality base pair reads. We next removed any sequences where the base pair length was 275 bp. We then combined all duplicate sequences and aligned the sequences to the SILVA_v123 bacterial reference alignment (obtained from <http://www.mothur.org/>.) We then removed any sequences that were outside the expected alignment region of V4, and pre-clustered any sequences that were differing by 2 bp or less. We then removed chimeras and any non-bacterial sequences, including those that align to Archaea, Chloroplasts, Eukaryotes, or Archaea. Lastly, we then clustered the sequences into operational taxonomic units (OTUs) at the 0.03 threshold (97% sequence similarity). These final OTU assignments for the sequences in each sample were then taken into further downstream alpha and beta diversity analyses and evaluation of differential abundance of OTUs between comparison groups.

2.3. Statistical analysis {#sec2.3}
-------------------------

Categorical variables were compared using Pearson\'s chi-square. As age was skewed, a general linear model was used to first apply a log transformation to normalize the age distribution. Microbiome analyses were performed using all sequences passing quality control. Multiple measures of diversity were used to see the level of agreement across metrics that evaluate a similar quality but using different approaches. Alpha diversity was measured by the number of observed OTUs, Shannon Index, and the inverse Simpson\'s Index. Observed OTUs provide information about richness (q = 0), while the Shannon index (q = 1) and inverse Simpson index (q = 2) increasingly add information about relative abundance ([@bib42]). Observed OTUs and the inverse Simpson\'s index were determined using mothur v.1.39.5 ([@bib36]). Shannon index was determined using the shannon function of *vegan* v.2.5--5 in RStudio ([@bib23]). Beta diversity was measured using Morisita-Horn (using Explicet v.2.10.5) and Bray-Curtis and Jaccard distances (using *phyloseq* v.1.28.0 in RStudio) ([@bib19]; [@bib30]). Bray-Curtis distances utilize relative abundance (similar to Shannon and inverse Simpson indices), while Jaccard distances only use presence/absence of community members (similar to richness) ([@bib40]). Morisita-Horn was used for pairwise comparison ([@bib42]). Importantly, alpha diversity was calculated without prior subsampling to maximize use of data obtained ([@bib20]); however, comparisons were made to subsampled data to ensure validity of our findings. General linear models (using STATA/IC v15.1) were used for comparison of alpha diversity measures between groups to account for differences in demographics and bacterial exposures, including method of delivery, duration of breastfeeding, attendance at daycare, and siblings in the home. Mixed effects general linear models were used for longitudinal comparisons 1) between children with CF of different ages and 2) between children with CF receiving CF transmembrane conductance regulator (CFTR) modulators, children with CF not receiving CFTR modulators, and healthy controls to adjust for repeated measures per subject. OTU and taxonomy tables were imported into RStudio for subsequent analyses using *phyloseq* v.1.28.0 and *DESeq2* v.1.24.0 to determine differential abundance and create principle coordinates analysis (PCoA) plots ([@bib17]; [@bib19]). Lastly, the adonis function of *vegan* v.2.5--5 was used to determine significant differences in the centroids and dispersion of the groups by permutational multivariate analysis of variance (PERMANOVA) using Bray-Curtis ("bray") and Jaccard ("jaccard") distances ([@bib23]). The strata argument was used to constrain permutations when assessing repeated patient samples.

3. Results {#sec3}
==========

3.1. Participant demographics and exposure history {#sec3.1}
--------------------------------------------------

Twenty-five children with CF aged 6 years or younger had clinical data and respiratory samples collected between February 2016 through April 2017, encompassing between 4 and 6 visits. Fifty healthy controls were enrolled and had clinical data and respiratory samples collected between October 2016 and May 2018 from a single visit. No differences were noted between the two groups with regard to demographics, excepting that children with CF were more likely to be white and healthy controls were more likely to be black (p = 0.002, [Table 1](#tbl1){ref-type="table"}). There were also no differences in common methods of bacterial exposures, specifically method of delivery, duration of breastfeeding, attendance at daycare or school, or siblings in the home. Children with CF were more likely to have received antibiotics within the last year (p \< 0.001, [Table 1](#tbl1){ref-type="table"}).Table 1Participant demographics, bacterial exposure, and antibiotic history[‡](#tbl1fnddagger){ref-type="table-fn"}.Table 1Cystic Fibrosis (n = 25)Healthy Control (n = 50)P valueAge (years) (mean, standard error)[∗](#tbl1fnlowast){ref-type="table-fn"}4.04 (0.29)3.72 (0.38)0.508Gender (n, %)[†](#tbl1fndagger){ref-type="table-fn"}0.870 Female13 (52)27 (54) Male12 (48)23 (46)Race (n, %)[†](#tbl1fndagger){ref-type="table-fn"}0.002 White13 (52)19 (38) Black4 (16)25 (50) Other8 (32)6 (12)Ethnicity (n, %)[†](#tbl1fndagger){ref-type="table-fn"}0.221 Hispanic7 (28)8 (16) Not Hispanic18 (72)42 (84)Delivery Method (n, %)[†](#tbl1fndagger){ref-type="table-fn"}0.814 Vaginal15 (65)34 (68) Cesarean8 (35)16 (32)Length of Breastfeeding (n,%)[†](#tbl1fndagger){ref-type="table-fn"}0.111 None9 (36)10 (20) \<3 months2 (8)8 (16) 3--6 months6 (24)14 (28) 6--12 months6 (24)5 (10) \>12 months2 (8)13 (26)Daycare or School (n, %)[†](#tbl1fndagger){ref-type="table-fn"}0.994 No8 (38)19 (38) Yes13 (62)31 (62)Siblings (n, %)[†](#tbl1fndagger){ref-type="table-fn"}0.697 No5 (20)12 (24) Yes20 (80)38 (76)Antibiotics Courses in the 12 months Preceding Sample Collection (n, %)[†](#tbl1fndagger){ref-type="table-fn"}\<0.001 None2 (8)38 (76) 1--2 courses10 (40)12 (24) 3--4 courses9 (36)0 (0) 5 or more courses4 (16)0 (0)[^1][^2][^3]

3.2. Results of 16S sequencing controls {#sec3.2}
---------------------------------------

A positive and negative sequencing control was included in each MiSeq run (n = 4). A mean of 9 sequences (range 6--12) were detected in the PCR-free water controls. A mean of 21,720 sequences (range 18,289--24,912) were detected in the ZymoBIOMICS Microbial Community Standards, with a mean sequencing error rate of 1.57 percent (range 1.56--1.59).

3.3. Comparisons in bacterial community composition between children with CF versus age similar healthy controls {#sec3.3}
----------------------------------------------------------------------------------------------------------------

A mean of 21,385 (range 2043--35,696) sequences were available for the CF samples and a mean of 21,218 (range 10,777--34,654) for healthy control samples. The relative abundance of bacteria identified in the upper airway microbiome differed between the baseline samples of children with CF and healthy controls ([Figure 1](#fig1){ref-type="fig"}). Using adjusted p values (with false discovery rate correction), six bacterial OTUs were more abundant in children with CF: three Rothia OTUs (OTU66 p \< 0.001, OTU3 p = 0.003, and OTU58 p = 0.047), one *Staphylococcus* OTU (OTU27 p = 0.003), and two *Streptococcus* OTUs (OTU7 p = 0.004 and OTU2 p = 0.006) ([Figure 2](#fig2){ref-type="fig"}). Conversely, fourteen bacterial OTUs were more abundant in healthy controls: four Leptotrichia OTUs (OTU25 p = 0.003, OTU11 p = 0.026, OTU53 p = 0.037, and OTU82 p = 0.049), Neisseriaceae_unclassified (OTU90 p = 0.006), Clostridiales_unclassified (OTU63 p = 0.007), Atopobium (OTU21 p = 0.009), Haemophilus (OTU20 p = 0.010), Catonella (OTU72 p = 0.015), Veillonella (OTU18 p = 0.019), Actinomyces (OTU12 p = 0.023), TM7_genus_incertae_sedis (OTU106 p = 0.038), Bacteroidetes_unclassified (OTU74 p = 0.049), and Parvimonas (OTU65 p = 0.049).Figure 1Relative taxonomic abundance of the upper airway microbiome of children with cystic fibrosis and healthy controls. Only the top 25 OTUs are included.Figure 1Figure 2Differential abundance of bacterial genera in the upper airway microbiome between children with cystic fibrosis and healthy controls. Bacterial genera on the left side of the graph with a negative fold change have a higher relative abundance in the healthy control samples compared to the cystic fibrosis samples. Bacterial genera on the right side of the graph with a positive fold change have a higher relative in the cystic fibrosis samples compared to the healthy control samples. All genera shown had adjusted p values \<0.05.Figure 2

3.4. Comparisons in microbial diversity between children with CF and age similar controls {#sec3.4}
-----------------------------------------------------------------------------------------

Children with CF had on average lower upper airway diversity in their baseline sample than age similar controls. Controlling age, race, ethnicity, length of breastfeeding, and having siblings, the number of OTUs was lower in children with CF compared to healthy controls (62.1 vs 83, p = 0.022; [Table 2](#tbl2){ref-type="table"}). There were similar trends for the Shannon diversity index (p = 0.057) and the inverse Simpson index (p = 0.118). Furthermore, alpha diversity measures of subsampled data (2043 sequences) showed congruent results ([Table 2](#tbl2){ref-type="table"}). Therefore, all available sequence data was used for subsequent diversity analyses. Beta diversity as measured by both Bray-Curtis and Jaccard distances were also different between children with CF and healthy controls (PERMANOVA R2 = 0.071, p = 0.001 and R2 = 0.054, p = 0.001 respectively, [Figure 3](#fig3){ref-type="fig"}).Table 2Alpha diversity Measures between children with CF and healthy controls.Table 2Cystic Fibrosis (n = 25)[†](#tbl2fndagger){ref-type="table-fn"}Healthy Control (n = 50)[†](#tbl2fndagger){ref-type="table-fn"}P value[†](#tbl2fndagger){ref-type="table-fn"}Cystic Fibrosis (n = 25)[‡](#tbl2fnddagger){ref-type="table-fn"}Healthy Control (n = 50)[‡](#tbl2fnddagger){ref-type="table-fn"}P value[‡](#tbl2fnddagger){ref-type="table-fn"}Number of OTUs[∗](#tbl2fnlowast){ref-type="table-fn"} (mean, standard error)62.1 (7.4)83 (4.4)0.02236.0 (3.2)43.0 (1.9)0.080Shannon Diversity Index[∗](#tbl2fnlowast){ref-type="table-fn"} (mean, standard error)2.09 (0.11)2.35 (0.07)0.0572.07 (0.11)2.34 (0.07)0.054Inverse Simpson Index[∗](#tbl2fnlowast){ref-type="table-fn"} (mean, standard error)5.70 (0.63)6.92 (0.38)0.1185.70 (0.63)6.92 (0.38)0.118[^4][^5][^6][^7]Figure 3Differences in community composition between children with cystic fibrosis versus healthy controls. Dissimilarities in bacterial genera using log transformed counts are shown based on cystic fibrosis versus control and age of the participant. (A) Bray-Curtis distance PCoA for cystic fibrosis versus healthy control samples. (B) Jaccard distance PCoA for cystic fibrosis versus healthy control samples. (C) Bray-Curtis distance PCoA based on age. (D). Jaccard distance PCoA based on age. PERMANOVA showed a significant difference for both cystic fibrosis versus healthy control samples (R2 = 0.071, p = 0.001 Bray, R2 = 0.054, p = 0.001 Jaccard) and based on age (R2 = 0.042, p = 0.001 Bray, R2 = 0.033, p = 0.002 Jaccard).Figure 3

3.5. Comparisons in demographics and clinical characteristics of children with CF based on age {#sec3.5}
----------------------------------------------------------------------------------------------

There were no significant differences in demographics, use of cycled inhaled antibiotics, or antibiotic courses received in the 12 months preceding the study period between those children with CF 0 to \<3 years of age at study enrollment (n = 12) and those who were ≥3--6 years of age at study enrollment (n = 13) ([Table 3](#tbl3){ref-type="table"}). Those in the older age group were more likely to be on a CFTR modulator than those in the younger group (p = 0.039), likely due to the FDA guidance for approved use of this product during the study period. When exploring visit specific information, those in the younger age group (n = 50 samples, n = 12 subjects) were more likely to have normal flora detected in clinical respiratory culture than children in the older age group (n = 59 samples, n = 13 subjects, OR 0.29, p = 0.023; [Table 3](#tbl3){ref-type="table"}). *Pseudomonas aeruginosa* (OR 2.72, p = 0.217) and other bacteria (OR 3.59, p = 0.110) were identified more often in clinical respiratory cultures in those in the older age group than those in the younger age group, although these results were not significant. Those in the older age group also had more sick visits during the 12 month study period (OR 2.09, p = 0.191), but again this did not achieve significance.Table 3Demographics, medications, treatments, and diversity measures based on age group.Table 3Age 0 to \<3 years (n = 12 study participants)Age ≥3--6 years (n = 13 study participants)Odds RatioP valueGender (n, % female)[∗](#tbl3fnlowast){ref-type="table-fn"}7 (58)6 (46)NA0.695Race (n, %)[∗](#tbl3fnlowast){ref-type="table-fn"}NA0.751 White7 (58)6 (46) Black1 (8)3 (23) Other4 (33)4 (31)Ethnicity (n, %)[∗](#tbl3fnlowast){ref-type="table-fn"}NA\>0.999 Hispanic or Latino4 (33)4 (31) Not Hispanic or Latino8 (67)9 (69)CFTR Genotype (n, %)NA0.683 F508del homozygous5 (42)6 (46) F508del heterozygous5 (42)3 (23) Other2 (17)4 (31)Inhaled antibiotics (n, % yes)[∗](#tbl3fnlowast){ref-type="table-fn"}3 (25)2 (15)NA0.645Antibiotics Courses in the 12 months Preceding Sample Collection (n, %)[∗](#tbl3fnlowast){ref-type="table-fn"}NA0.537 None2 (17)0 (0) 1--2 courses5 (42)5 (38.5) 3--4 courses4 (33)5 (38.5) 5 or more courses1 (8)3 (23)CFTR modulator[†](#tbl3fndagger){ref-type="table-fn"} (n, % yes)0 (0)5 (38)NA0.039Age 0 to \<3 years (n = 50 study samples)Age ≥3--6 years (n = 59 study samples)Odds Ratio[¶](#tbl3fnpara){ref-type="table-fn"}P valueRespiratory Culture (n, % yes)[‡](#tbl3fnddagger){ref-type="table-fn"}Normal respiratory flora44 (88)40 (68)0.290.023*Staphylococcus aureus*2 (4)3 (5)1.290.802*Pseudomonas aeruginosa*2 (4)6 (10)2.720.217Other bacteria[§](#tbl3fnsection){ref-type="table-fn"}3 (6)11 (19)3.590.110Number of Sick Visits (n, % yes)7 (14)15 (25)2.090.191Oral Antibiotics (n, % yes)7 (14)13 (22)1.740.305IV Antibiotics (n, % yes)0 (0)1 (2)NANASteroids (n, % yes)0 (0)4 (7)NANANumber of OTUs[∗∗](#tbl3fnlowastlowast){ref-type="table-fn"} (mean, standard error)63.9 (5.9)70.1 (5.6)NA0.455Shannon Diversity Index[∗∗](#tbl3fnlowastlowast){ref-type="table-fn"}(mean, standard error)2.15 (0.08)2.25 (0.08)NA0.371Inverse Simpson Index[∗∗](#tbl3fnlowastlowast){ref-type="table-fn"} (mean, standard error)6.13 (0.41)6.52 (0.39)NA0.482Morisita-Horn between subsequent encounters[∗∗](#tbl3fnlowastlowast){ref-type="table-fn"} (mean, standard error)0.78 (0.04)0.69 (0.04)NA0.070[^8][^9][^10][^11][^12][^13][^14]

3.6. Comparisons in microbial diversity and community composition of children with CF based on age {#sec3.6}
--------------------------------------------------------------------------------------------------

Alpha diversity measures were similar between the younger (age 0 to \<3 years) and older (age ≥3--6 years) children with CF, incorporating all visits and controlling for repeated patient measures ([Table 3](#tbl3){ref-type="table"}). Community composition tended to remain more similar between visits in younger children with CF compared to older children (Morisita-Horn 0.78 versus 0.69, p = 0.070). When we controlled for nature of the visit (sick versus well) at the time of sample collection instead of for repeated patient samples, no significant differences were noted in alpha diversity measures. However, the difference in Morisita-Horn reached significance (p = 0.028).

No significant differences were noted in beta diversity between the younger and older children with CF as measured by both Bray-Curtis and Jaccard distances (PERMANOVA R2 = 0.016, p \> 0.999 and R2 = 0.015, p \> 0.999 respectively, [Figure 4](#fig4){ref-type="fig"}). No differences in the relative abundance of specific taxa were identified between the younger and older children with CF (p \> 0.05).Figure 4Differences in community composition in children with cystic fibrosis based on age. Dissimilarities in bacterial genera using log transformed counts are shown based on age 0 to \<3 years (Group A) versus age ≥3--6 years (Group B). (A) Bray-Curtis distance PCoA (PERMANOVA R2 = 0.016, p \> 0.999). (B) Jaccard distance PCoA (PERMANOVA R2 = 0.015, p \> 0.999).Figure 4

3.7. Effects of CFTR modulation in microbial diversity and community composition {#sec3.7}
--------------------------------------------------------------------------------

To assess any impacts of CFTR modulation on the differences in microbial diversity, we performed a sub-analysis of children ≥2 years of age (the youngest FDA approved age to start CFTR modulators during the study period). Those children on CFTR modulation (n = 5) had significantly more study visits during the study period compared to children not receiving CFTR modulators (n = 12) (p = 0.029), but had no increase in the number of pulmonary exacerbations or antibiotic treatment courses during the study period ([Table 4](#tbl4){ref-type="table"}). Likewise, there was no significant difference in inhaled antibiotic use or antibiotic treatment courses in the 12 months preceding the study period between the two groups. Respiratory samples from 35 healthy controls were compared to 25 samples from 5 children with CF receiving CFTR modulators and 51 samples from 12 children with CF not receiving CFTR modulators. While respiratory samples from healthy controls retained the highest levels of alpha diversity, samples from children with CF receiving CFTR modulators had higher alpha diversity compared to children with CF not receiving CFTR modulators ([Table 4](#tbl4){ref-type="table"}), and was significantly different between groups for all measures (all p \< 0.001). However, community composition as assessed by Bray-Curtis and Jaccard distances showed no differences between healthy children, children with CF on modulator therapy, or children with CF not receiving CFTR modulators (PERMANOVA Bray-Curtis R2 = 0.071, p \> 0.999 and Jaccard R2 = 0.058, p \> 0.999, [Figure 5](#fig5){ref-type="fig"}).Table 4Demographics and Effect of CFTR modulators on alpha diversity.Table 4CFTR no (n = 12 study participants)CFTR yes (n = 5 study participants)HC (n = 35 study participants)P valueInhaled antibiotics (n, % yes)2 (17)1 (20)NA\>0.999Antibiotics Courses in the 12 months Preceding Sample Collection (n, %)[†](#tbl4fndagger){ref-type="table-fn"}\<0.001 (all)\
\>0.999 (CFTR no vs yes) None0 (0)0 (0)27 (77) 1--2 courses5 (42)2 (40)8 (23) 3--4 courses4 (33)2 (40)0 (0) 5 or more courses3 (25)1 (20)0 (0) Total Visits during the Study Period (mean, SD)[‡](#tbl4fnddagger){ref-type="table-fn"}4.3 (0.45)5 (0.71)NA0.029 Sick Visits during the Study Period (mean, SD)[‡](#tbl4fnddagger){ref-type="table-fn"}1.1 (1.24)0.8 (0.84)NA0.781 Antibiotic Courses in the Study Period (mean, SD)[‡](#tbl4fnddagger){ref-type="table-fn"}1.1 (1.24)0.8 (0.84)NA0.781CFTR no (n = 51 study samples)CFTR yes (n = 25 study samples)HC (n = 35 study samples)P valueNumber of OTUs[∗](#tbl4fnlowast){ref-type="table-fn"} (mean, standard error)63.7 (4.9)74.7 (7.4)97.6 (4.4)\<0.001Shannon Diversity Index[∗](#tbl4fnlowast){ref-type="table-fn"} (mean, standard error)2.11 (0.07)2.34 (0.10)2.56 (0.07)\<0.001Inverse Simpson Index[∗](#tbl4fnlowast){ref-type="table-fn"} (mean, standard error)5.78 (0.41)7.23 (0.59)7.96 (0.43)\<0.001[^15][^16][^17][^18]Figure 5Effect of CFTR modulation on community composition. Dissimilarities in bacterial genera using log transformed counts are shown for children with CF receiving CFTR modulators (CFTR_Y), children with CF not receiving CFTR modulators (CFTR_N), and age similar healthy controls (HC). (A) Bray-Curtis distance PCoA (PERMANOVA R2 = 0.071, p \> 0.999). (B) Jaccard distance PCoA (PERMANOVA R2 = 0.058, p \> 0.999).Figure 5

4. Discussion {#sec4}
=============

In this study, we found that infants and young children with CF have decreased microbial diversity compared to age similar healthy controls. This is consistent with prior studies of the lower airways. One of the early studies focused on differences in microbial richness between infants and young children with CF (n = 13, mean age 3.95 years) and non-CF controls (n = 9, mean age 3.78 years) found an average of 130 species in the BAL fluid of children with CF and 167 species in non-CF controls ([@bib29]). A more recent study found that microbial richness was reduced in lower airway samples of infants with CF (n = 21, median age 1.8 months) compared to non-CF controls (n = 10, median age 5 months), with a 95% confidence interval of difference of 1.13--11.83 OTUs ([@bib8]). Larger comparison studies analyzing the upper airway via nasopharyngeal (NP) swab have not found significant differences in alpha diversity; however, these studies were limited to the first year of life ([@bib21]; [@bib26]).

We also found differences in microbial composition between our cohort of infants and young children with CF and age similar healthy controls. Our significant differences in beta diversity as measured by Bray-Curtis and Jaccard distances were similar to those described in prior studies of both the lower airway via BAL fluid and the upper airway via NP swabs ([@bib8]; [@bib21]; [@bib26]; [@bib29]). In particular, *Staphylococcus* species were more abundant in infants and children with CF than their age-matched counterparts, which has been described by other groups and is consistent with our knowledge that *S. aureus* is an early pathogen in CF disease ([@bib7], [@bib8]; [@bib21]; [@bib26]; [@bib33]). In our cohort, we also found that *Rothia* and two *Streptococcus* OTUs were more abundant in infants and young children with CF than age similar healthy controls. *Streptococcus* is a common oral flora, and has frequently been found to be dominant taxa in the lower respiratory microbiome of young children with CF ([@bib7]; [@bib15]; [@bib24]; [@bib44]). *Rothia* has previously been described as part of the core microbiota of upper airway samples in adults with CF, but has not consistently been identified in younger children ([@bib5]; [@bib44]).

The number of antibiotic courses in the last 12 months was significantly higher in infants and children with CF than the age similar healthy controls in our cohort. This may have contributed in part to the differences we saw in both relative bacterial abundance and alpha diversity between our two groups. Cumulative antibiotic use is associated with decreased diversity in older children and adults with CF ([@bib46]). A study of the upper airway in infants with CF found that initiation of prophylactic antibiotics significantly modified the microbial community, and the change persisted longitudinally ([@bib21]). Another study of infants with CF found prophylactic antibiotics were related to an increase in gram-negative bacteria ([@bib26]). Further studies are required to test the impact of intermittent courses of antibiotics on the microbiome in infants and young children with CF.

When testing for age related differences in longitudinally collected OP swabs from infants and children with CF, we found that younger children (age 0 to \<3 years) were more likely to culture normal respiratory flora than older children age (≥3--6 years). Additionally, in sequencing analyses younger children had a trend toward more stability in microbial composition between visits than older children. No differences were noted in alpha diversity between the two groups. This was in contrast to a large multicenter cross-sectional study that found that younger children (\<2 years) had higher diversity than preschool and older children (2--5 or 5--10 years), although no significance was noted between those age groups ([@bib44]). A single center longitudinal study of 48 children with CF 0--6 years of age found that overall microbial diversity was inversely correlated to age ([@bib7]).

When examining beta diversity and community composition, we did not find any differences between younger and older children with CF, and no specific taxa were identified as being differentially abundant between the two groups. This is in contrast to a cross-sectional study of BAL fluid from 46 infants and young children with CF, which found that the lower airway microbiome of children 1--2 years of age was dominated by oral flora (*Streptococcus*, *Prevotella*, and *Veillonella*), while the lower airway microbiome of children 3--5 years of age were dominated by CF pathogens (*Haemophilus*, *Staphylococcus*, *Moraxella*, and *Pseudomonas*) ([@bib22]). Similar differences in community composition based on age were found in a multicenter study of BAL fluid collected for microbiome analyses, with children \<2 years of age having approximately 50% of reads attributed to nontraditional taxa (*Streptococcus*, *Neisseria*, *Porphyromonas*, *Prevotella*, and *Veillonella*) compared to 30% CF pathogens (*Pseudomonas*, *Staphylococcus*, *Stenotrophomonas*, *Haemophilus*, and *Burkholderia*) ([@bib44]). Conversely, children 2--5 years of age had BAL fluid microbiomes composed of roughly 50% traditional CF pathogens and 30% nontraditional taxa ([@bib44]). From these studies together, it seems likely that diversity remains high when the airway is composed of normal airway flora, but decreases as typical CF pathogens become residents of the microbiome. This pattern would also be consistent with what has previously been established in adults with CF ([@bib5]; [@bib6]; [@bib44]).

CFTR modulators are newly developed and available drugs which aim to improve the function of the CFTR protein ([@bib4]; [@bib11]). When assessing for an impact of CFTR modulation on airway microbial diversity, we found significant differences between children with CF not receiving CFTR modulators, children with CF receiving CFTR modulators, and healthy controls. While diversity was highest for healthy controls, those receiving CFTR modulators had the next highest levels of diversity. These findings corroborate previously published studies in older children and adults with CF. The first study of changes in the airway microbiome related to ivacaftor use assessed paired sputum from 14 sub-study participants ([@bib32]). In this older cohort (mean age 27 years), the authors found that while sputum bacterial diversity did not change with treatment, the combined relative abundance of traditional CF bacterial pathogens trended downward (mean change -13.9, p = 0.11) ([@bib32]). Another study of 3 patients with longitudinally collected sputum samples pre- and post-ivacaftor initiation found that microbial communities became more dissimilar after ivacaftor initiation, suggesting a change in community composition and relative abundance ([@bib2]). A more recent study of 12 adult subjects (mean age 29.5 years), 8 of whom were chronically infected with *Pseudomonas aeruginosa*, found that all experienced a significant decline in *P. aeruginosa* following ivacaftor initiation that lasted for at least 1 year ([@bib13]). Additionally, the decline in the relative abundance of *P. aeruginosa* was accompanied by reciprocal changes in the relative abundance of nonconventional organisms, leading to increased richness and Shannon diversity ([@bib13]). While this sub-analysis was only performed on small number of patients, it adds to this body of CFTR literature by demonstrating that CFTR modulation is significantly associated with increased microbial richness and diversity, bringing levels closer to those seen in age similar healthy children.

Limitations in our study include the use of 16S rRNA sequencing, which can lead to primer bias and only describes the microbial community at the level of bacterial genera, missing species level differentiation of bacteria (and unknown bacteria) as well as viral and fungal components of the microbiome. While we did not find statistical significance in common causes of bacterial exposures between the children with CF and the healthy controls, this does not signify the absence of confounding in a modest sized study, especially in light of the difference in race identified between the two groups. This study also did not address concurrent viral infection, which also contributes to respiratory health and can impact the microbiome. Future studies would need to control for these confounders. Additionally, the total numbers of children with CF who participated in the longitudinal study was small and likely led to an inability to detect differences that may have been present between the younger and older age groups. In the CFTR modulator sub-analysis, those receiving modulators had significantly more study visits and samples collected during the study period, which may have introduced biases to our analysis. Lastly, this study relied on information obtained from OP swabs and did not include a BAL comparison group, and prior studies have shown discordance between cultures and microbiome analyses of OP swabs versus sputum or BAL ([@bib1]; [@bib3]; [@bib10]; [@bib16]; [@bib25]; [@bib28]; [@bib31]; [@bib45]).

5. Conclusions {#sec5}
==============

In summary, we found that children with CF have reduced microbial diversity of the upper airway microbiome compared to age similar healthy controls. The decrease in bacterial diversity appears to start in early childhood and, in addition to the presence of CF disease, it may be associated with antibiotic exposure. Longitudinal samples collected over time of children with CF showed a trend toward less stability in the microbial composition of older children, possibly related to increased exacerbations and infection with traditional CF pathogens. Lastly, the addition of CFTR modulators increased airway microbial diversity closer to the levels seen in healthy controls. We did not find antibiotic use to be a factor affecting differences in microbial diversity among children with CF, but our study was not designed to answer that specific question. Longitudinal studies in a larger cohort are needed to better define the acquisition of the diverse microbial community in young children with CF. More specifically, we need to improve our understanding of how early initiation of CFTR modulators and administration antibiotics early in life affect microbial diversity and clinical outcomes.
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[^1]: For children with CF, the sample used in this analysis was the first sample collected in the longitudinal series.

[^2]: Generalized linear model adjusting for age skew.

[^3]: Chi-squared.

[^4]: OTUs, operational taxonomic units.

[^5]: Generalized linear model, adjusting for age, race, ethnicity, length of breastfeeding, and siblings.

[^6]: Using all available sequencing data.

[^7]: Using subsampled sequencing data (2043 sequences).

[^8]: CFTR, cystic fibrosis transmembrane conductance regulator.

[^9]: Fisher\'s exact test.

[^10]: Ivacaftor n = 3, lumacaftor/ivacaftor n = 2.

[^11]: Logistic regression, adjusting for repeated patient visits.

[^12]: OR less than 1 more likely in Age 0 to \<3 years, greater than 1 more likely in Age ≥3--6 years.

[^13]: Other bacteria include *Stenotrophomonas maltophilia* (x5), *Streptococcus pyogenes* (x4), *Streptococcus agalactiae* (x3), *Chryseobacterium species* (x2), and *Elizabethkingia meningoseptica*.

[^14]: Mixed effects generalized linear model, adjusting for repeated patient visits (p-value reported in the table) and whether the sample was collected at a sick or well visit (starting with OTUs, p-value was 0.223, 0.194, 0.334, and 0.028).

[^15]: CFTR, cystic fibrosis transmembrane conductance regulator; HC, healthy control.

[^16]: Fisher\'s exact test.

[^17]: Wilcoxon rank-sum test.

[^18]: Mixed effects generalized linear model, adjusting for repeated patient visits.
